Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$17.78 - $42.39 $130,683 - $311,566
-7,350 Closed
0 $0
Q4 2021

Jan 28, 2022

SELL
$47.84 - $64.34 $361,335 - $485,960
-7,553 Reduced 50.68%
7,350 $430,000
Q3 2021

Oct 14, 2021

BUY
$59.27 - $95.73 $883,300 - $1.43 Million
14,903 New
14,903 $883,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $346M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Hamilton Lane Advisors LLC Portfolio

Follow Hamilton Lane Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamilton Lane Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hamilton Lane Advisors LLC with notifications on news.